🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ StockGenie AI

TruBridge, Inc. TBRG R2K

Healthcare · Health Information Services · United States
https://trubridge.com

TruBridge, Inc. provides healthcare solutions and services for community hospitals, clinics, and other healthcare systems in the United States and internationally. The company operates in two segments, Financial Health and Patient Care. It offers revenue cycle management (RCM) products, including patient liability estimate, eligibility verification, claim scrubbing and submission, remittance management, denial/audit management, and contract management services; RCM services, such as accounts receivable management, private pay service, medical coding, revenue cycle consulting, and other additional insurance and patient billing services; consulting, business intelligence, staffing, and administrative services; cloud services, backup and recovery, collaboration and connectivity, security services, systems management, and help desk services; and encoder solutions. The company also provides TruBridge HER, a software solution platform which offers various software applications using one fully integrated system designed to streamline the flow of information to the primary functional areas of community hospitals. In addition, it offers acute care support and maintenance services comprising total system support, national client conference, continuing education, software releases, hardware replacement, cloud electronic health record, forms and supplies, instantPHR, and CHBase. Further, the company provides business management services; acute care EHR solutions and related services for community hospitals, and their physician clinics; and patient engagement and technology solutions. The company was formerly known as Computer Programs and Systems, Inc. and changed its name to TruBridge, Inc. in March 2024. TruBridge, Inc. was founded in 1979 and is headquartered in Mobile, Alabama.

READ MORE ›
$25.96
+8.48% 1Y

Market & Price

Market Cap
$389.38M
Current Price
$25.96
High / Low (52W)
$25.96 / $14.00
Beta
1.31

Valuation

Stock P/E
89.52
Industry PE
23.65
Forward P/E
8.73
PEG Ratio
0.32
Book Value
$12.14
Price to Book
2.14
P/S
1.13
EV/EBITDA
15.30
Dividend Yield
-

Profitability & Returns

ROCE
4.70%
ROE
2.54%
ROA
3.24%
Profit Margin
1.27%
Op Margin
4.70%
EPS (Latest Qtr)
$0.03
EPS (TTM)
$0.29

Balance Sheet & Liquidity

Debt/Equity
0.94
Quick Ratio
1.44
Current Ratio
1.78
Debt
$168.46M
Total Assets
$402.53M
Current Assets
$104.64M
Working Capital
$46.68M

Ownership

Promoter Holding
15.95%
Chg in Prom Hold
-
FII / Inst Holding
69.72%
Chg in FII Hold
-

Financial Snapshot

Enterprise Value
$517.39M
Total Revenue (TTM)
$345.90M
EBITDA
$33.82M
Free Cash Flow
$37.16M
Operating Cash Flow
$46.66M
Shares Outstanding
15.00M
Gross Margin
53.22%
Payout Ratio
0.00%

Growth (CAGR)

Revenue 5Y
2.02%
Profit 5Y
-35.02%
Revenue (YoY)
-1.10%
Earnings (YoY)
0.00%

PROS

  • Generates positive free cash flow.
  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

  • Trading at a high P/E of 89.5.
  • Earnings shrank at -35.0% CAGR over 5 years.
  • RSI at 81 suggests overbought conditions.

* The pros and cons are auto-generated from financial metrics.

Price Chart

Robinhood TradingView StockAnalysis

Fundamental Growth

Figures from the latest reported periods. CAGR is computed across the displayed window (quarterly CAGR is annualised assuming 4 quarters per year).

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 TBRG TruBridge, Inc. R2K 25.96 89.52 $389.38M - 4.70% 2.54% 2.02% -35.02%
2 LLY Eli Lilly and Company SPX 1,105.00 39.21 $985.37B 0.63% 38.44% 107.46% 31.69% 48.96%
3 JNJ Johnson & Johnson SPX 225.33 26.11 $542.42B 2.38% 23.13% 26.42% 5.60% 14.32%
4 UNH UnitedHealth Group Incorporated SPX 380.31 28.66 $345.38B 2.32% 9.60% 12.18% 11.35% -15.69%
5 MRK Merck & Co., Inc. SPX 118.72 33.44 $293.22B 2.86% 20.66% 18.94% 3.12% 7.93%
6 TMO Thermo Fisher Scientific Inc. SPX 492.51 27.11 $183.03B 0.38% 9.17% 13.52% -0.27% -1.19%
7 AMGN Amgen Inc. NDXSPX 336.79 23.42 $181.77B 2.99% 18.02% 101.32% 11.77% 5.58%
8 GILD Gilead Sciences, Inc. NDXSPX 134.43 18.29 $166.90B 2.44% 22.92% 43.36% 2.57% 22.83%
9 ISRG Intuitive Surgical, Inc. NDXSPXAI 424.64 51.53 $150.39B - 15.96% 17.23% 17.39% 29.26%
Ad space

Quarterly Results

Figures in USD.

Metric Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Revenue -------64.08M67.68M67.11M78.06M70.88M67.91M69.30M72.33M69.14M66.16M68.70M70.64M69.76M59.55M68.33M66.85M68.00M68.53M70.09M77.87M82.73M82.83M86.23M84.62M82.71M84.12M85.60M84.70M87.21M85.73M86.11M87.79M86.27M
Cost of Revenue -----------------------------------39.51M41.27M42.05M40.14M38.35M
Gross Profit 24.71M22.73M22.57M36.09M34.91M32.77M33.49M32.70M35.99M34.38M44.20M39.09M34.85M36.11M39.68M37.12M34.53M35.91M36.58M36.11M30.11M35.42M34.61M34.85M33.89M35.29M41.19M40.67M38.02M42.06M40.49M----47.70M44.46M44.06M47.65M47.92M
Operating Expenses -----------------------------------39.53M40.83M39.99M42.67M44.87M
Operating Income 8.39M4.26M4.61M776.00K5.26M4.24M4.09M3.23M4.45M5.62M-18.12M7.65M2.23M5.36M9.65M6.05M3.62M6.01M8.91M6.13M2.75M6.20M5.97M4.91M7.74M4.53M8.99M4.59M4.94M6.29M-1.91M-5.21M-588.00K-2.15M2.81M8.16M3.63M4.07M4.98M3.06M
EBITDA -----------------------------------14.72M10.37M11.09M6.29M10.08M
Interest Expense -----------------------------------3.38M3.06M3.00M2.87M2.63M
Pretax Income -----------------------------------4.92M698.00K1.35M-3.10M582.00K
Tax Provision -----------------------------------4.46M-1.88M-4.25M1.19M76.00K
Net Income 5.90M3.54M3.39M-1.66M2.00M1.60M2.00M246.00K1.59M2.29M-21.54M3.97M328.00K5.75M7.59M3.44M1.66M4.13M11.23M4.09M1.76M5.27M3.12M4.14M6.14M2.74M8.11M3.08M2.16M3.08M-2.84M-3.56M-1.85M-4.39M-9.15M459.00K2.58M5.60M-4.29M506.00K
Diluted EPS 0.520.310.30-0.130.150.120.150.020.110.17-1.570.290.020.410.540.240.120.290.780.280.120.360.220.280.420.190.550.210.150.21-0.20-0.24-0.13-0.29-0.610.030.170.37-0.370.03
R&D Expense 3.57M3.56M-7.19M8.18M8.40M-8.08M8.41M8.25M-8.76M9.31M9.30M-9.23M9.30M9.16M-8.27M8.37M8.55M-8.43M6.47M7.70M8.06M8.11M7.99M8.35M8.77M9.78M10.69M8.21M7.74M8.25M8.11M8.17M-7.45M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue -------267.27M276.93M280.41M274.63M264.49M-326.65M336.96M342.20M346.84M
Cost of Revenue -------------166.54M175.56M168.92M162.97M
Gross Profit 53.26M64.38M79.41M80.66M93.74M113.95M94.46M133.73M147.27M149.73M144.15M136.25M-160.11M161.40M173.28M183.86M
Operating Expenses -------------137.32M168.83M166.91M163.03M
Operating Income 23.37M29.10M41.29M41.28M50.24M49.59M25.09M14.38M-4.81M24.88M24.58M21.05M-22.78M-7.43M6.37M20.83M
EBITDA -------------47.73M-18.62M34.27M42.46M
Interest Expense -------------6.32M12.52M16.17M12.32M
Pretax Income -------------18.08M-57.46M-10.47M3.87M
Tax Provision -------------2.21M-9.33M10.48M-485.00K
Net Income 15.18M18.74M25.83M29.97M32.74M32.92M18.34M3.93M-17.42M17.63M20.47M14.25M-15.87M-48.13M-20.95M4.35M
Diluted EPS 1.391.712.342.712.952.941.620.29-1.271.261.430.98-1.08-3.15-1.550.29
R&D Expense -2.33M2.45M2.76M2.76M14.62M14.23M29.09M33.74M36.37M36.86M33.46M32.81M31.90M38.83M35.45M32.56M

Compounded Sales Growth

5 Years:2.02%
1 Year:-1.10%

Compounded Profit Growth

5 Years:-35.02%
1 Year:0.00%

Stock Price Performance

1 Year:+8.48%
6 Months:+15.17%
3 Months:+34.58%
1 Month:+0.89%

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --62.74M75.64M77.09M92.53M99.32M92.79M339.15M318.22M327.75M339.59M326.27M-430.96M431.78M395.82M402.53M
Current Assets --------------74.56M108.81M93.69M104.64M
Cash & Equivalents 11.74M4.39M2.94M6.66M8.91M11.73M23.79M24.95M2.22M520.00K5.73M7.36M12.67M-6.95M3.85M12.32M24.85M
Inventory --------------784.00K475.00K767.00K623.00K
Receivables --------------51.31M56.24M52.95M54.97M
Total Liabilities -------17.42M181.18M182.13M167.96M155.24M126.27M-199.25M247.80M228.75M224.57M
Current Liabilities --14.49M16.67M17.72M21.45M18.16M17.42M30.95M40.85M38.50M41.93M37.44M-44.45M48.23M56.00M57.96M
Long Term Debt -------0146.99M136.61M124.58M99.43M73.36M-136.39M195.27M168.60M161.24M
Total Debt --------------147.24M203.29M174.81M166.74M
Total Equity 40.56M42.69M46.46M57.38M57.20M69.08M80.78M75.37M157.97M136.09M159.78M184.35M200.00M-231.71M183.97M167.07M177.96M
Shares Outstanding --------------14.91M15.12M15.52M15.68M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 8.81M19.64M33.54M32.21M29.05M38.95M30.88M2.10M23.64M23.93M43.60M49.14M-32.38M-522.00K31.14M36.97M
Investing Cash Flow -2.16M-5.31M-14.03M1.48M-3.68M-1.52M-598.00K-151.79M-726.00K-978.00K-12.49M-6.66M--62.73M-58.53M5.12M-14.72M
Financing Cash Flow -14.01M-15.78M-15.79M-31.44M-22.55M-25.36M-29.12M126.95M-24.62M-17.74M-29.48M-37.16M-25.88M55.95M-27.74M-9.71M
Capital Expenditure -829.10K-5.09M-10.85M-4.36M-3.63M-1.47M-448.00K-39.00K-726.00K-978.00K-1.76M-3.34M--19.37M-21.82M-18.11M-17.13M
Free Cash Flow 7.98M14.55M22.69M27.84M25.42M37.48M30.43M2.07M22.92M22.95M41.84M45.81M-13.01M-22.35M13.04M19.84M
Net Change in Cash --------------4.48M-3.10M8.52M12.53M
Share Buybacks ---------001.26M1.31M11.92M2.58M404.00K1.95M
Dividends Paid 15.77M15.79M15.89M31.44M22.64M25.53M28.94M25.09M11.64M5.62M5.73M4.34M00---

Ratios (Annual)

Figures in %.

Metric Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % -------50.0%53.2%53.4%52.5%51.5%-49.0%47.9%50.6%53.0%
Operating Margin % -------5.4%-1.7%8.9%9.0%8.0%-7.0%-2.2%1.9%6.0%
Net Margin % -------1.5%-6.3%6.3%7.5%5.4%-4.9%-14.3%-6.1%1.3%
ROE % 35.6%40.3%45.0%52.4%47.4%40.8%24.3%2.5%-12.8%11.0%11.1%7.1%-6.8%-26.2%-12.5%2.4%
ROCE % -60.3%70.0%69.5%70.7%61.1%33.3%4.7%-1.7%8.6%8.3%7.3%-5.9%-1.9%1.9%6.0%

Shareholding Pattern

Insiders
15.95%
Institutions
69.72%
Public Float
82.94%

Top Institutional Holders

#Holder% HeldSharesValue
1 Nellore Capital Management LLC 6.59% 988.45K $25.66M
2 Blackrock Inc. 4.89% 732.87K $19.03M
3 Vanguard Capital Management LLC 3.85% 577.38K $14.99M
4 Dimensional Fund Advisors LP 3.75% 562.85K $14.61M
5 MARTIN & CO INC /TN/ 2.99% 448.65K $11.65M
6 Ameriprise Financial, Inc. 1.97% 295.48K $7.67M
7 Federated Hermes, Inc. 1.95% 292.41K $7.59M
8 Kennedy Capital Management, LLC 1.89% 283.84K $7.37M
9 Geode Capital Management, LLC 1.67% 250.97K $6.52M
10 State Street Corporation 1.30% 195.22K $5.07M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for TBRG

No recent headlines available.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks